Precision BioSciences
DTIL
95 hedge funds and large institutions have $139M invested in Precision BioSciences in 2026 Q2 according to their latest regulatory filings, with 31 funds opening new positions, 31 increasing their positions, 14 reducing their positions, and 13 closing their positions.
138% more first-time investments, than exits
New positions opened: 31 | Existing positions closed: 13
121% more repeat investments, than reductions
Existing positions increased: 31 | Existing positions reduced: 14
58% more capital invested
Capital invested by funds: $88.1M → $139M (+$50.8M)
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
22% more funds holding
Funds holding: 78 → 95 (+17)
3.19% more ownership
Funds ownership: 65.32% → 68.5% (+3.2%)
6% less call options, than puts
Call options by funds: $92K | Put options by funds: $98K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$6.85M |
| 2 |
Mackenzie Financial
Toronto Ontario,
Ontario, Canada
|
+$3.38M |
| 3 |
BL
Bleichroeder LP
New York
|
+$2.5M |
| 4 |
State Street
Boston,
Massachusetts
|
+$2.49M |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$2.35M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EAM
Empery Asset Management
New York
|
-$8.39M |
| 2 |
OCA
Octagon Capital Advisors
New York
|
-$6.24M |
| 3 |
Marshall Wace
London,
United Kingdom
|
-$2.29M |
| 4 |
Renaissance Technologies
New York
|
-$1.09M |
| 5 |
Alyeska Investment Group
Chicago,
Illinois
|
-$764K |
DTIL Hedge Fund Activity: Q2 2026 in Review
95 of the 8,318 institutional investors tracked by Wall St. Rank reported a position in Precision BioSciences (DTIL) for Q2 2026, worth a combined $139M — up 58% from $88.1M a quarter earlier.
Buyers outnumbered sellers: 31 funds opened new DTIL positions and 13 closed out — a net gain of 18 holders — while 31 added to existing stakes and 14 trimmed.
The largest buyer was BlackRock, adding an estimated $6.85M. The largest seller was Empery Asset Management, cutting an estimated $8.39M.
- 95 institutional investors held Precision BioSciences (DTIL) as of Q2 2026, up from 78 in Q1 2026.
- Funds reported $139M of Precision BioSciences stock for Q2 2026, up 58% quarter-over-quarter.
- 31 funds opened new Precision BioSciences positions in Q2 2026 and 13 closed out, a net change of +18 holders.
- The largest Precision BioSciences buyer in Q2 2026 was BlackRock, an estimated $6.85M added.
- The largest Precision BioSciences seller in Q2 2026 was Empery Asset Management, an estimated $8.39M sold.
Based on aggregated 13F filings for Q2 2026.